Autopsy report · NCT01600742

Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis

“Sponsor stops to provide the study drug.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 4 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Taiwan University Hospital

Sponsor type

University, hospital or other

Conditions

Brain Metastasis

Interventions

Vorinostat; Placebo

Participants

4

Sites

1

Countries

Taiwan

Trials that died the same way

• Multi-center Complex Atrial Tachycardia High-Resolution Mapping Registry (MATH)
  “The sponsor has decided to stop the study” (79% match in meaning)
• the Health Crisis at the Healthcare Professionals, Careers and Non-careers, a Month After the Containment Period
  “the sponsor decided to stop the study” (78% match in meaning)
• Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
  “Sponsor decision to stop the study” (77% match in meaning)
• Study of Satraplatin (JM-216) in Combination With Docetaxel
  “Sponsor decided to discontinue study drug development.” (77% match in meaning)
• A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease
  “Sponsor stopped the study” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.